Poseida Therapeutics Announces Pricing of Public Offering of Common Stock
Poseida Therapeutics, priced an underwritten public offering of 20 million shares at $3.50 per share, aiming to generate approximately $70 million in gross proceeds. The offering is expected to close on August 8, 2022, and will fund the development of their innovative gene therapy platforms. Underwriters, including Piper Sandler and William Blair, have a 30-day option to purchase an additional 3 million shares. The offering will be made under a shelf registration previously filed with the SEC.
- Offering size: 20 million shares priced at $3.50 each, grossing approximately $70 million.
- Potential to support the development of innovative gene therapies.
- Dilution risk for existing shareholders due to the public offering.
SAN DIEGO, Aug. 4, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of
Piper Sandler and William Blair & Company, L.L.C. are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. and BTIG, LLC are also acting as book-running managers for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A copy of the final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Piper Sandler, Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com; or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687 or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Poseida Therapeutics Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing our proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. We have discovered and are developing a broad portfolio of product candidates in a variety of indications based on our core proprietary platforms, including our non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-specific Gene Editing System and nanoparticle- and AAV-based gene delivery technologies. Our core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable us to engineer our portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the timing, terms and completion of the proposed public offering. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Poseida's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the satisfaction of customary closing conditions related to the offering and the other risks described in Poseida's filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Poseida undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-pricing-of-public-offering-of-common-stock-301599986.html
SOURCE Poseida Therapeutics, Inc.
FAQ
What is the pricing of Poseida Therapeutics' public offering?
How much capital will Poseida Therapeutics raise from the offering?
When is the expected closing date for Poseida's public offering?
What is the purpose of Poseida Therapeutics' public offering?
Who are the underwriters for Poseida Therapeutics' public offering?
